The 86th Scientific Sessions of the American Diabetes Association (ADA 2026)

New Orleans, Louisiana, US 05 June 2026 - 08 June 2026

Berobenatide a promising addition to the current GLP-1 RA roster

In the phase II VESPER-2 trial, the investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) berobenatide shows robust reductions in weight and HbA1c in adults with obesity/overweight and type 2 diabetes (T2D).

Berobenatide a promising addition to the current GLP-1 RA roster

18 hours ago

Adjunctive HBOT beneficial for DFUs

a day ago by

A meta-analysis presented at ADA 2026 supports the benefits of hyperbaric oxygen therapy (HBOT) for ulcer healing and reducing the risk of major amputation in individuals with diabetic foot ulcers (DFUs).

Adjunctive HBOT beneficial for DFUs

a day ago

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 by

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026 by

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 by

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026 by

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026 by

Daily treatment with oral orforglipron, when added to titrated insulin glargine, has been shown to be beneficial in individuals with inadequately controlled type 2 diabetes (T2D) in the phase 3 ACHIEVE-5 trial.

Add-on orforglipron improves outcomes in T2D patients on insulin glargine

17 Jun 2026